Table 1.

Characteristics of the included studies

Study (by country/city)	Study design	City	Study period	Source of data	Study population	Genomic region for sequencing	N, HCV‐viraemic a	N, eligible b , c	%, HIV+
Australia & New Zealand							237	111 (18)	100
Bartlett et al. [13]	Cross‐sectional study	Multi‐centre	2004 to 2015	Clinic/hospital	HCV‐mono & HIV/HCV‐coinfected individuals	C/E2	237	111 (18) d	100
China							1209	86 (3)	≥60.5
Jiao et al. [14]	Cross‐sectional study	Beijing	2010 to 2011	Screening	Drug users, MSM & general population	C/E1 & NS5B	157	5	NA
Tian et al. [15]	Cross‐sectional study	Guangxi	2009 to 2011	Surveillance	HIV‐positive individuals	5’NC/C, C/E2, NS5B	76	17 (3)	100
Yuan et al. [16]	Cross‐sectional study	Guangdong	2007 to 2015	Clinic/hospital	HCV‐infected individuals	C/E1	426	17	NA
Tian et al. [15]	Cross‐sectional study	Henan	2009 to 2011	Surveillance	HIV‐positive individuals	5’NC/C, C/E2, NS5B	133	19	100
Zhao et al. [17]	Cross‐sectional study	Hubei	2007 to 2010	Surveillance	HIV‐positive individuals	C, NS5B	66	7	100
Peng et al. [18]	Cross‐sectional study	Hubei	2013 to 2014	Clinic/hospital	HCV‐infected individuals	C/E1, NS5B	252	10	≥90
Yang et al. [19]	Cross‐sectional study	Yunnan	2014	Clinic/hospital	HCV‐mono & HIV/HCV‐coinfected individuals	C/E1, NS5B	99	11	NA
Hong Kong							58	40	100
Sun et al. [20]	Cross‐sectional study	Hong Kong	2010 to 2016	Clinic/hospital	HIV/HCV‐coinfected individuals	NS5B	58	40	100
India							70	15	NA
Medhi et al. [21]	Cross‐sectional study	Multi‐centre	2005 to 2008	Clinic/hospital	Individuals with liver diseases	NS5B	70	15	NA
Indonesia							7	6	0
Hadikusumo et al. [22]	Cross‐sectional study	Surabaya	2012	Screening	Transgender individuals	NS5B	7	6	0
Japan							98	64	100
Ishida et al. [23]	Cross‐sectional study	Tokyo	1997 to 2015	Clinic/hospital	HIV‐positive individuals	Full genome	98	64	100
Pakistan							1364	78	NA
Ahmad et al. [24]	Cross‐sectional study	Lahore	2007 to 2009	Clinic/hospital	HCV‐infected individuals	5’NC	1364	78	NA
Taiwan							168	149	100
Sun et al. [25]	Cohort study	Taipei	1994 to 2010	Clinic/hospital	HIV‐positive individuals	NS5B	30	21	100
Sun et al. [20]	Cross‐sectional study	Taipei	2010 to 2016	Clinic/hospital	HIV/HCV‐coinfected individuals	NS5B	138	128	100
Total							3211	549 (21)	≥75.8

^aMay not equal the sample size of the whole study

^bnumber of eligible cases (a subject who was determined to have acquired HCV through sexual contact with an identifiable molecular subtype)

^cnumber of samples with history of injection drug use in parentheses

^deighteen samples from Australia who acquired HCV by injection drug use (as determined by clinician based on reported risk behaviours) with homosexual exposure for HIV acquisition were included.